When to Skip Regional Nodal Radiation in Breast Cancer
When neoadjuvant chemotherapy turns positive lymph nodes negative, 5-year survival outcomes are the same whether patients have regional nodal irradiation or not.
Stay updated with breaking news from Lymph Nodes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
When neoadjuvant chemotherapy turns positive lymph nodes negative, 5-year survival outcomes are the same whether patients have regional nodal irradiation or not.
For patients whose breast cancer converted from lymph node-positive to lymph node-negative disease after neoadjuvant chemotherapy, skipping adjuvant regional nodal irradiation (RNI) did not increase the risk of disease recurrence or death five years after surgery, according to results from the NRG Oncology/NSABP B-51/RTOG 1304 clinical trial presented at the San Antonio Breast Cancer Symposium, held December 5-9, 2023.
Levetiracetam and clobazam can cause a rare but serious drug reaction with eosinophilia and systemic symptoms that can be life threatening if not diagnosed and treated quickly, the FDA warns.
In this third episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, discuss key advancements made in the surgical treatment of patients with breast cancer.
Investigators say their meta-analysis of 16 trials spanning six decades highlights the benefits patients and oncologists can expect from regional lymph node radiation for early breast cancer.